Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Kidney Ultrasound Findings According to Kidney Function in Sickle Cell Anemia.

Patel R, Kang S, Valeshabad AK, Shah BN, Han J, Gowhari M, Molokie RE, Xie K, Lash JP, Gordeuk VR, Saraf SL.

Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25602. [Epub ahead of print] No abstract available.

PMID:
31379007
2.

Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit.

Gordeuk VR, Miasnikova GY, Sergueeva AI, Lorenzo FR, Zhang X, Song J, Stockton DW, Prchal JT.

Haematologica. 2019 Jul 9. pii: haematol.2019.216267. doi: 10.3324/haematol.2019.216267. [Epub ahead of print]

3.

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators.

N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.

PMID:
31199090
4.

Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series.

Han J, Gowhari M, Gordeuk VR, Saraf SL.

Obes Surg. 2019 Jun 10. doi: 10.1007/s11695-019-03983-5. [Epub ahead of print]

PMID:
31183783
5.

Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al.

Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS.

Br J Haematol. 2019 May 8. doi: 10.1111/bjh.15949. [Epub ahead of print] No abstract available.

PMID:
31066029
6.

Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

Gordeuk VR, Key NS, Prchal JT.

Haematologica. 2019 Apr;104(4):653-658. doi: 10.3324/haematol.2018.210732. Epub 2019 Mar 14. Review.

7.

The morbidity and mortality of end stage renal disease in sickle cell disease.

Viner M, Zhou J, Allison D, Han J, Molokie RE, Jain S, Gowhari M, Gordeuk VR, Calip G, Saraf SL.

Am J Hematol. 2019 May;94(5):E138-E141. doi: 10.1002/ajh.25439. Epub 2019 Mar 1. No abstract available.

PMID:
30773675
8.

Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.

Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS.

Br J Haematol. 2019 Apr;185(1):116-127. doi: 10.1111/bjh.15773. Epub 2019 Feb 3.

PMID:
30714090
9.

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Akingbola TS, Tayo BO, Ezekekwu CA, Sonubi O, Zhang X, Saraf SL, Molokie R, Hsu LL, Han J, Cooper RS, Gordeuk VR.

Am J Hematol. 2019 Apr;94(4):E112-E115. doi: 10.1002/ajh.25412. Epub 2019 Feb 6. No abstract available.

PMID:
30663794
10.

White Paper: Pathways to Progress in Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa.

Hsu L, Nnodu OE, Brown BJ, Tluway F, King S, Dogara LG, Patil C, Shevkoplyas SS, Lettre G, Cooper RS, Gordeuk VR, Tayo BO.

J Trop Dis Public Health. 2018;6(2):260. doi: 10.4172/2329-891X.1000260. Epub 2018 Jul 10.

11.

Sickle Cell Disease Clinical Trials and Phenotypes.

Ezekekwu CA, Kotila TR, Akingbola TS, Lettre G, Gordeuk VR, Cooper RS, DeBaun MR, Inusa B, Tayo BO; Africa Sickle Cell Research Network.

J Trop Dis Public Health. 2018;6(2):259. doi: 10.4172/2329-891X.1000259. Epub 2018 Apr 8.

12.

Use of metformin in patients with sickle cell disease.

Han J, Saraf SL, Molokie RE, Gordeuk VR.

Am J Hematol. 2019 Jan;94(1):E13-E15. doi: 10.1002/ajh.25313. Epub 2018 Nov 9. No abstract available.

PMID:
30328140
13.

High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.

Han J, Saraf SL, Gowhari M, Jain S, Molokie RE, Gordeuk VR.

Am J Hematol. 2019 Jan;94(1):E5-E7. doi: 10.1002/ajh.25311. Epub 2018 Oct 31. No abstract available.

PMID:
30299555
14.

The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease.

DiMartino LD, Baumann AA, Hsu LL, Kanter J, Gordeuk VR, Glassberg J, Treadwell MJ, Melvin CL, Telfair J, Klesges LM, King A, Wun T, Shah N, Gibson RW, Hankins JS; Sickle Cell Disease Implementation Consortium.

Am J Hematol. 2018 Dec;93(12):E391-E395. doi: 10.1002/ajh.25282. Epub 2018 Oct 17. No abstract available.

15.

HMOX1 and acute kidney injury in sickle cell anemia.

Saraf SL, Viner M, Rischall A, Raslan R, Shah BN, Zhang X, Han J, Gowhari M, Jain S, Molokie RE, Machado RF, Lash JP, Gordeuk VR.

Blood. 2018 Oct 11;132(15):1621-1625. doi: 10.1182/blood-2018-05-853929. Epub 2018 Aug 23. No abstract available.

PMID:
30139825
16.

Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease.

Raslan R, Shah BN, Zhang X, Kanias T, Han J, Machado RF, Gladwin MT, Gordeuk VR, Saraf SL.

Am J Hematol. 2018 Nov;93(11):E376-E380. doi: 10.1002/ajh.25258. Epub 2018 Oct 17. No abstract available.

PMID:
30117177
17.

A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971.

18.

Risk factors for vitamin D deficiency in sickle cell disease.

Han J, Zhang X, Saraf SL, Gowhari M, Molokie RE, Hassan J, Jain S, Shah BN, Abbasi T, Machado RF, Gordeuk VR.

Br J Haematol. 2018 Jun;181(6):828-835. doi: 10.1111/bjh.15270. Epub 2018 May 16.

19.

Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.

Zhou J, Han J, Nutescu EA, Gordeuk VR, Saraf SL, Calip GS.

Br J Haematol. 2018 Jul;182(2):259-270. doi: 10.1111/bjh.15396. Epub 2018 May 16.

20.

Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria.

Tayo BO, Akingbola TS, Saraf SL, Shah BN, Ezekekwu CA, Sonubi O, Hsu LL, Cooper RS, Gordeuk VR.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25143. [Epub ahead of print] No abstract available.

21.

Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease.

Saraf SL, Oh AL, Patel PR, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Jain S, Peace D, Quigley JG, Khan I, Molokie RE, Mahmud N, Gordeuk VR, Rondelli D.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1759-1765. doi: 10.1016/j.bbmt.2018.03.031. Epub 2018 Apr 12.

22.

Patrolling the endothelium in sickle cell disease.

Gordeuk VR.

Blood. 2018 Apr 5;131(14):1503-1505. doi: 10.1182/blood-2018-02-832139. No abstract available.

23.

Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk.

Zhang DL, Wu J, Shah BN, Greutélaers KC, Ghosh MC, Ollivierre H, Su XZ, Thuma PE, Bedu-Addo G, Mockenhaupt FP, Gordeuk VR, Rouault TA.

Science. 2018 Mar 30;359(6383):1520-1523. doi: 10.1126/science.aal2022.

PMID:
29599243
24.

Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods.

Campbell-Lee SA, Gvozdjan K, Choi KM, Chen YF, Saraf SL, Hsu LL, Gordeuk VR, Strauss RG, Triulzi DJ.

Transfusion. 2018 Jul;58(7):1588-1596. doi: 10.1111/trf.14588. Epub 2018 Mar 23.

PMID:
29570817
25.

Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models.

Saraf SL, Sysol JR, Susma A, Setty S, Zhang X, Gudehithlu KP, Arruda JAL, Singh AK, Machado RF, Gordeuk VR.

Transl Res. 2018 Jul;197:1-11. doi: 10.1016/j.trsl.2018.01.007. Epub 2018 Feb 2.

26.

Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia.

Jerebtsova M, Saraf SL, Soni S, Afangbedji N, Lin X, Raslan R, Gordeuk VR, Nekhai S.

Am J Hematol. 2018 Aug;93(4):E107-E109. doi: 10.1002/ajh.25036. Epub 2018 Feb 5. No abstract available.

27.

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease.

Field JJ, Majerus E, Gordeuk VR, Gowhari M, Hoppe C, Heeney MM, Achebe M, George A, Chu H, Sheehan B, Puligandla M, Neuberg D, Lin G, Linden J, Nathan DG.

Blood Adv. 2017 Aug 28;1(20):1645-1649. doi: 10.1182/bloodadvances.2017009613. eCollection 2017 Sep 12. Erratum in: Blood Adv. 2017 Oct 19;1(23 ):2058.

28.

Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis.

Jerebtsova M, Saraf SL, Lin X, Lee G, Adjei EA, Kumari N, Afangbedji N, Raslan R, McLean C, Gordeuk VR, Nekhai S.

Am J Hematol. 2018 Feb;93(2):E45-E47. doi: 10.1002/ajh.24965. Epub 2017 Nov 27. No abstract available.

29.

Ethnic and genetic factors of iron status in women of reproductive age.

Gordeuk VR, Brannon PM.

Am J Clin Nutr. 2017 Dec;106(Suppl 6):1594S-1599S. doi: 10.3945/ajcn.117.155853. Epub 2017 Oct 25.

30.

Program expansion of a day hospital dedicated to manage sickle cell pain.

Han J, Saraf SL, Kavoliunaite L, Jain S, Hassan J, Hsu LL, Molokie RE, Gordeuk VR, Gowhari M.

Am J Hematol. 2018 Jan;93(1):E20-E21. doi: 10.1002/ajh.24938. Epub 2017 Oct 31. No abstract available.

31.

Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts.

Saraf SL, Akingbola TS, Shah BN, Ezekekwu CA, Sonubi O, Zhang X, Hsu LL, Gladwin MT, Machado RF, Cooper RS, Gordeuk VR, Tayo BO.

Blood Adv. 2017 Apr 25;1(11):693-698. doi: 10.1182/bloodadvances.2017005231.

32.

Characterization of opioid use in sickle cell disease.

Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS.

Pharmacoepidemiol Drug Saf. 2018 May;27(5):479-486. doi: 10.1002/pds.4291. Epub 2017 Aug 16.

33.

Erythropoiesis-stimulating agents in sickle cell anaemia.

Han J, Zhou J, Kondragunta V, Zhang X, Molokie RE, Gowhari M, Hassan J, Jain S, Calip GS, Gordeuk VR, Saraf SL.

Br J Haematol. 2018 Aug;182(4):602-605. doi: 10.1111/bjh.14846. Epub 2017 Jul 27. No abstract available.

34.

Use of anti-inflammatory analgesics in sickle-cell disease.

Han J, Saraf SL, Lash JP, Gordeuk VR.

J Clin Pharm Ther. 2017 Oct;42(5):656-660. doi: 10.1111/jcpt.12592. Epub 2017 Jul 10.

35.

Hemochromatosis, iron-loading anemia, and SMAD.

Gordeuk VR.

Blood. 2017 Jul 6;130(1):6-7. doi: 10.1182/blood-2017-05-782656. No abstract available.

36.

Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.

Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P, George A, Raj AB, Nero AC, Terrell CE, McCord L, Lane A, Ackerman HC, Yang Y, Niss O, Taylor MD, Devarajan P, Malik P.

Am J Hematol. 2017 Sep;92(9):E520-E528. doi: 10.1002/ajh.24810. Epub 2017 Jul 19.

37.

Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.

Han J, Zhang X, Oderinde J, Saraf SL, Gowhari M, Hassan J, Jain S, Gordeuk VR, Molokie RE.

Haematologica. 2017 Aug;102(8):e282-e284. doi: 10.3324/haematol.2017.169128. Epub 2017 May 4. No abstract available.

38.

Association of circulating transcriptomic profiles with mortality in sickle cell disease.

Desai AA, Lei Z, Bahroos N, Maienschein-Cline M, Saraf SL, Zhang X, Shah BN, Nouraie SM, Abbasi T, Patel AR, Lang RM, Lussier Y, Garcia JGN, Gordeuk VR, Machado RF.

Blood. 2017 Jun 1;129(22):3009-3016. doi: 10.1182/blood-2016-11-752279. Epub 2017 Apr 3.

39.

Gain-of-function EGLN1 prolyl hydroxylase (PHD2 D4E:C127S) in combination with EPAS1 (HIF-2α) polymorphism lowers hemoglobin concentration in Tibetan highlanders.

Tashi T, Scott Reading N, Wuren T, Zhang X, Moore LG, Hu H, Tang F, Shestakova A, Lorenzo F, Burjanivova T, Koul P, Guchhait P, Wittwer CT, Julian CG, Shah B, Huff CD, Gordeuk VR, Prchal JT, Ge R.

J Mol Med (Berl). 2017 Jun;95(6):665-670. doi: 10.1007/s00109-017-1519-3. Epub 2017 Feb 23.

PMID:
28233034
40.

Preventing delayed hemolytic transfusion reactions in sickle cell disease.

Castro O, Oneal P, Medina A, Onojobi G, Gordeuk VR.

Transfusion. 2016 Nov;56(11):2899-2900. doi: 10.1111/trf.13784. No abstract available.

PMID:
28211954
41.

A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.

Zhang X, Shah BN, Zhang W, Saraf SL, Miasnikova G, Sergueeva A, Ammosova T, Niu X, Nouraie M, Nekhai S, Castro O, Gladwin MT, Prchal JT, Garcia JG, Machado RF, Gordeuk VR.

Hum Mol Genet. 2016 Oct 15;25(20):4601-4609. doi: 10.1093/hmg/ddw299.

42.

Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia.

Sergueeva A, Miasnikova G, Shah BN, Song J, Lisina E, Okhotin DJ, Nouraie M, Nekhai S, Ammosova T, Niu XM, Prchal JT, Zhang X, Gordeuk VR.

Haematologica. 2017 May;102(5):e166-e169. doi: 10.3324/haematol.2016.158170. Epub 2017 Jan 19. No abstract available.

43.

Reply to Ruan X et al: "A comment on pattern of opioid use in sickle cell disease".

Han J, Saraf SL, Machado RF, Gordeuk VR.

Am J Hematol. 2017 Apr;92(4):E43. doi: 10.1002/ajh.24646. Epub 2017 Feb 7. No abstract available.

44.

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.

Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP.

N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.

45.

ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.

Kim K, Li J, Barazia A, Tseng A, Youn SW, Abbadessa G, Yu Y, Schwartz B, Andrews RK, Gordeuk VR, Cho J.

Haematologica. 2017 Feb;102(2):246-259. doi: 10.3324/haematol.2016.151159. Epub 2016 Oct 6.

46.

Patterns of opioid use in sickle cell disease.

Han J, Saraf SL, Zhang X, Gowhari M, Molokie RE, Hassan J, Alhandalous C, Jain S, Younge J, Abbasi T, Machado RF, Gordeuk VR.

Am J Hematol. 2016 Nov;91(11):1102-1106. doi: 10.1002/ajh.24498. Epub 2016 Aug 8.

47.

APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia.

Saraf SL, Shah BN, Zhang X, Han J, Tayo BO, Abbasi T, Ostrower A, Guzman E, Molokie RE, Gowhari M, Hassan J, Jain S, Cooper RS, Machado RF, Lash JP, Gordeuk VR.

Haematologica. 2017 Jan;102(1):e1-e6. doi: 10.3324/haematol.2016.154153. Epub 2016 Sep 22. No abstract available.

48.

Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center.

Han J, Bhat S, Gowhari M, Gordeuk VR, Saraf SL.

Pharmacotherapy. 2016 Nov;36(11):1166-1172. doi: 10.1002/phar.1834. Epub 2016 Oct 3.

49.

Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease.

Duarte JD, Desai AA, Sysol JR, Abbasi T, Patel AR, Lang RM, Gupta A, Garcia JG, Gordeuk VR, Machado RF.

PLoS One. 2016 Sep 16;11(9):e0163013. doi: 10.1371/journal.pone.0163013. eCollection 2016.

50.

Safety of chronic transdermal fentanyl use in patients receiving hemodialysis.

Han J, Saraf SL, Gordeuk VR, Gowhari M.

Am J Health Syst Pharm. 2016 Jul 1;73(13):947-8. doi: 10.2146/ajhp150748. No abstract available.

Supplemental Content

Loading ...
Support Center